From the first ride to the frontlines of rare cancer research
Cycle for Survival has fueled bold science at MSK, from early-stage ideas to lifesaving treatments, and has helped fund what’s next in the fight against rare cancers.
MSK Chatbot
Past event
20 Years Closer Impact Event
On January 28, 2026 — the 20th anniversary of the first Cycle for Survival ride — supporters nationwide united for a virtual event to hear from MSK leaders about the program’s impact on rare cancer research and the breakthroughs this community makes possible.
Featured speakers
Jeffrey Drebin, MD, PhD
As MSK’s Chief Physician Executive, Dr. Drebin leads our academic clinical departments and the clinical practice plan in addition to hospital-based research, medical education, training programs, and faculty affairs. He holds the Murray F. Brennan chair in surgery.
Ross Levine, MD
Dr. Levine is MSK's newly appointed Chief Scientific Officer, Senior Vice President of Translational Research in Memorial Hospital, and holds the Edward P. Evans Endowed Chair for Myelodysplastic Syndromes at MSK.
Selwyn M. Vickers, MD, FACS
Dr. Vickers is the President and CEO of MSK and holds the Douglas A. Warner III Chair.
Dave Linn
Moderator
Dave is the co-founder of Cycle for Survival and a founding Principal at Oak Point Partners.
What does 20 years of rare cancer progress look like?
On January 28, we celebrated two decades of determination, discovery, and community. MSK leaders and Cycle for Survival supporters shared updates about the breakthroughs you have made possible.
biotech
campaign
Voices of the movement
We celebrate the stories of the people who’ve shaped this movement — and the support that continues to drive hope and progress.
Program highlights
- A historic moment
- From breakthroughs to what’s next
Cycle for Survival Co-Founder Dave Linn moderated a discussion with MSK’s President and CEO Selwyn M. Vickers, MD, FACS; Chief Physician Executive Jeffrey Drebin, MD, PhD; and Chief Scientific Officer Ross Levine, MD about their vision for the future of cancer care, and how they believe Cycle for Survival can help MSK researchers find an effective treatment for every person with rare cancer.
This was a truly unprecedented moment for our community: Never before had MSK’s top leaders united at a Cycle for Survival event. Their collaboration underscores the importance of this moment and the extraordinary progress we’ve made together.
Cycle for Survival helped kick-start the field of precision oncology, providing seed funding for MSK-IMPACT®, the first FDA-authorized tumor sequencing test, and MSK-ACCESS®, a groundbreaking liquid biopsy tool. These innovations have changed how cancer is diagnosed and treated — not just for rare cancers but for all cancers.
Now, we’re still ahead of the curve, investing in data science, immunotherapy, and precision diagnostics to shape a better future for people with rare cancers. The pace of progress has accelerated in the past 20 years, thanks in part to scientific and technological advances funded by this community, and the next 5 to 10 years of rare cancer research may be as transformative as the last two decades.
A historic moment
Cycle for Survival Co-Founder Dave Linn moderated a discussion with MSK’s President and CEO Selwyn M. Vickers, MD, FACS; Chief Physician Executive Jeffrey Drebin, MD, PhD; and Chief Scientific Officer Ross Levine, MD about their vision for the future of cancer care, and how they believe Cycle for Survival can help MSK researchers find an effective treatment for every person with rare cancer.
This was a truly unprecedented moment for our community: Never before had MSK’s top leaders united at a Cycle for Survival event. Their collaboration underscores the importance of this moment and the extraordinary progress we’ve made together.
From breakthroughs to what’s next
Cycle for Survival helped kick-start the field of precision oncology, providing seed funding for MSK-IMPACT®, the first FDA-authorized tumor sequencing test, and MSK-ACCESS®, a groundbreaking liquid biopsy tool. These innovations have changed how cancer is diagnosed and treated — not just for rare cancers but for all cancers.
Now, we’re still ahead of the curve, investing in data science, immunotherapy, and precision diagnostics to shape a better future for people with rare cancers. The pace of progress has accelerated in the past 20 years, thanks in part to scientific and technological advances funded by this community, and the next 5 to 10 years of rare cancer research may be as transformative as the last two decades.
Questions? Contact us.
We are happy to answer any questions you have about fundraising, participating, donating, or celebrating with us!
Cycle for Survival
mail_outline
cycleforsurvival@mskcc.org
call
888-72-CYCLE
